MEDI 8968

Drug Profile

MEDI 8968

Alternative Names: AMG-108; Anti-IL-1R MAb; MEDI-8968

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Hidradenitis suppurativa; Osteoarthritis; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 21 Jul 2016 AstraZeneca terminates a phase II trial in Hidradenitis suppurativa in USA (SC) (NCT01838499)
  • 31 Jul 2014 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA, United Kingdom, Bulgaria, Hungary, Czech Republic, Latvia, Lithuania, Poland, Ukraine and the Philippines (SC)
  • 31 Jul 2014 Discontinued - Phase-II for Hidradenitis suppurativa in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top